Pasireotide (SOM230) is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

BACKGROUND: Pasireotide (SOM230), a long acting somatostatin analogue (LAR) has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, glucose levels, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12 month-old condi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Quinn, Thomas J., Yuan, Ziqiang, Adem, Asha, Geha, Rula, Vrikshajanani, Chakravarthy, Koba, Wade, Fine, Eugene, Hughes, David T., Schmid, Herbert, Libutti, Steven K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732168/
https://ncbi.nlm.nih.gov/pubmed/23102680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2012.08.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados